{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-XNW9S0VY/55cb2b76-1910-47db-941c-52916e330b72/HTML","dcterms:extent":"47 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-XNW9S0VY/81b18313-8f82-4068-b94e-7f96f1949442/PDF","dcterms:extent":"90 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-XNW9S0VY/0dc803f9-174d-4a0c-a7eb-42bc443b372e/TEXT","dcterms:extent":"47 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-XNW9S0VY","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2005","dc:creator":["Tršinar, Mihaela","Vovk, Tomaž"],"dc:format":[{"@xml:lang":"sl","#text":"letnik:56"},{"@xml:lang":"sl","#text":"8 strani"},{"@xml:lang":"sl","#text":"številka:posebna številka"},{"@xml:lang":"sl","#text":"str. 89-96"}],"dc:identifier":["ISSN:0014-8229","COBISSID:1731185","URN:URN:NBN:SI:doc-XNW9S0VY"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"interakcije"},{"@xml:lang":"sl","#text":"jemanje zdravil"},{"@xml:lang":"sl","#text":"starostniki"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Interakcije med zdravili za starostnike-teoretičen in praktičen vidik|"},"dc:description":[{"@xml:lang":"sl","#text":"The incidence of diseases increases with age, consequently the consumption of drugs is significantly higher in elderly than in other populations. Polytherapy, pharmacokinetic and pharmacodinamic alternations in elderly are probably one of the major factors that place the elderly population at higher risk of developing clinically significant drug-drug interactions. Pharmacokinetic drug interactions can occur at all pharmacokinetical levels, however the most of them appear at the drug metabolism and excretion level because of the impairments of both levels in elderly. On the other hand, pharmacodinamic drug interactions occure when two or more used drugs have synergistic or antagonistic pharmacological activities. The most frequent and dangerous reported drug-drug interactions in elderly include combinations of warfarin and nonsteroidal anti-inflammatory drugs, sulfonamides, macrolide antibiotics, quinolone antibiotics or phenytoinč combinations of angiotensin converting enzyme inhibitors and potassium supplements or spironolaconeč combinations of digoxin and amiodarone or verapamil and combinations of theophylline and quinolone antibiotics. Pharmaceutical intervention plays an important role in improvement of pharmacotherapy in elderly. The cooperation between pharmacist and physicians is one of the main key for improvement of pharmacotherapy in elderly"},{"@xml:lang":"sl","#text":"S staranjem se pogostost obolevnosti ljudi bistveno poveoeuje, zato starostniki jemljejo nesorazmerno več zdravil kot ostala populacija. Politerapija, farmakokinetske in farmakodinamske spremembe so verjetno med glavnimi vzroki za pogost pojav klinično pomebnih interakcij med zdravili pri starostnikih. Farmakokinetske interakcije med zdravili pri starostnikih potekajo na vseh nivojih, vendar večina klinično pomembnih farmakokinetskih interakcij nastane na nivoju metabolizma in eliminacije zdravil, saj sta oba procesa pri starostnikih pomembno upočasnjena. Poleg farmakokinetskih interakcij so pri starostnikih pomembne tudi farmakodinamske interakcije med zdravili, ki nastanejo takrat, ko imajo sočasno uporabljena zdravila sinergistično oz. antagonistično farmakološko delovanje. Najpogostejše in najnevarnejše poročane interakcije med zdravili pri starostnikih zajemajo kombinacije varfarina z nesteroidnimi protivnetnimi učinkovinami, sulfonamidi, makrolidnimi antibiotiki, kinoloni ali fenitoinom, kombinacije zaviralcev angiotenzinske konvertaze z nadomestki kalija ali spironolaktonom, kombinacije digoksina z amiodaronom ali verapamilom ter kombinacije teofilina in kinolonov. Farmacevtska intervencija predstavlja pomemben doprinos k izboljšanju terapije starostnikov. Za rešitev problemov povezanih s terapijo je ključnega pomena sodelovanje med zdravnikom in farmacevtom"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-XNW9S0VY","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-XNW9S0VY"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-XNW9S0VY/81b18313-8f82-4068-b94e-7f96f1949442/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-XNW9S0VY/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-XNW9S0VY"}}}}